Sorrento Therapeutics Inc
OTC:SRNE
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Sorrento Therapeutics Inc
OTC:SRNE
|
US |
|
G
|
Games Workshop Group PLC
F:G7W
|
UK |
|
B
|
Becton Dickinson and Co
DUS:BOX
|
US |
|
nCino OpCo, Inc.
NASDAQ:NCNO
|
US |
|
SBM Offshore NV
OTC:SBFFF
|
NL |
|
Canopy Growth Corp
TSX:WEED
|
CA |
|
GS Holdings Ltd
SGX:43A
|
SG |
|
M
|
Marathon Digital Holdings Inc
XMUN:M44
|
US |
|
BNCCorp Inc
OTC:BNCC
|
US |
|
C
|
Caleres Inc
F:BRP
|
US |
|
Krispy Kreme Inc
NASDAQ:DNUT
|
US |
|
N
|
Novartis AG
DUS:NOT
|
CH |
|
X
|
X-Fab Silicon Foundries Europese Vennootschap
F:XFB
|
BE |
|
T
|
Tan Phu Viet Nam JSC
VN:TPP
|
VN |
Intrinsic Value
There is not enough data to reliably calculate the intrinsic value for Sorrento Therapeutics Inc.
Do our valuations actually work? See backtest results .
Fundamental Analysis
What Sorrento Therapeutics Does
Sorrento Therapeutics, Inc. engages in the research, development, and manufacture of biopharmaceutical products. The company is headquartered in San Diego, California and currently employs 949 full-time employees. The company went IPO on 2007-01-19. The firm is engaged in developing a portfolio of next-generation treatments for cancer, infectious diseases and pain. The company is also developing Resiniferatoxin (RTX), a naturally occurring non-opioid ultra-potent transient receptor potential vanilloid-1 agonist.
- Headquarters
- United States of America US
- Employees
- 949
- IPO date
- Jan 19, 2007
